Affimed (NASDAQ:AFMD) Price Target Cut to $15.00 by Analysts at Wells Fargo & Company

Affimed (NASDAQ:AFMD) had its target price lowered by Wells Fargo & Company from $20.00 to $15.00 in a report issued on Thursday morning,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock.

Several other equities research analysts also recently issued reports on AFMD. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a report on Tuesday, November 19th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Affimed in a research note on Tuesday. Finally, Stifel Nicolaus dropped their target price on Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a report on Friday, November 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Affimed presently has an average rating of “Moderate Buy” and an average target price of $13.50.

Affimed Price Performance

NASDAQ AFMD opened at $2.18 on Thursday. The firm’s fifty day moving average price is $3.10 and its two-hundred day moving average price is $4.19. Affimed has a 1 year low of $2.02 and a 1 year high of $8.95. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13.

Institutional Trading of Affimed

Institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC bought a new stake in Affimed during the third quarter worth $44,000. Choreo LLC bought a new stake in shares of Affimed during the 2nd quarter worth $54,000. FMR LLC raised its stake in Affimed by 30.0% during the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares in the last quarter. Intellectus Partners LLC boosted its stake in shares of Affimed by 12.2% in the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 10,250 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after buying an additional 15,108 shares in the last quarter. Institutional investors own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.